This study is for patients with advanced or stage II and III colon or rectal cancer. The
primary purpose of this research study is to determine if a particular protein in the
patient's blood will change when they receive treatment with a drug called oxaliplatin, which
is used to treat the colon or rectal cancer. This protein is called ERCC-1. It is thought
that the amount of this protein in the blood could influence the manner in which the patient
responds to oxaliplatin.
Phase:
N/A
Details
Lead Sponsor:
Albert Einstein College of Medicine Montefiore Medical Center